Enfortumab vedotin plus pembrolizumab for recurrent metastatic urothelial carcinoma following adjuvant nivolumab - Lan Inoki; Saizo Fujimoto; Mamoru Hashimoto; Yutaka Yamamoto; Teruo Inamoto; Keita Tamura; Takuhisa Nukaya; Kiyoshi Takahara; Wataru Fukuokaya; Takafumi Yanagisawa; Yuki Yoshikawa; Ryoichi Maenosono; et al. (Japanese Journal of Clinical Oncology, 2026)